Over 1.3 million Americans are affected by rheumatoid arthritis. Rheumatoid arthritis does not have a cure, so treatment options are targeted toward the driving immunologic mechanism, which controls the symptoms of inflammation, joint pain and swelling, and fatigue.
Fortunately, there are research studies looking at investigational drugs to slow the progression of this condition and prevent permanent joint damage. Although there has been significant advancement in Rheumatoid therapeutics over the last decade, patients still have limited treatment options and some do not respond well to the available treatment options. The contRAst Program is aiming to change that for the better.
The contRAst program is looking at a new drug that will slow the progression of rheumatoid arthritis in adults. This program is composed of three different studies for RA patients: the contRAst-1 Study, the contRAst-2 Study, and the contRAst-3 Study.
Patients who participate will have a chance to take part in the long-term study. Qualified patients may receive medication and care from their local doctor at no cost. A concierge travel service may be an option should a patient not be able to reach the study center on their own.
If you are interested in the contRAst Program, fill out the form below or call (281) 766-7886 and ask for a member of the clinical research division. Our team can help determine if you qualify for the study.